6/26/2013 11:11:04 AM
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
COPENHAGEN, Denmark--(BUSINESS WIRE)--Symphogen, a private biopharmaceutical company developing recombinant antibody mixtures, announced today that it has received a milestone payment from Merck KGaA, Darmstadt, Germany, related to the successful achievement of specific development objectives for Sym004, an investigational antibody mixture targeting the epidermal growth factor receptor (EGFR).
Help employers find you! Check out all the jobs and post your resume.
comments powered by